Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes

Authors: Rahul Aggarwal MDa, Tian Zhang MDa, Eric J. Small MDa, and Andrew J. Armstrong MD, ScMa
View More View Less
  • a From the Department of Medicine, Division of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, and Department of Medicine, and Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham, North Carolina.

Neuroendocrine prostate cancer (NEPC) encompasses various clinical contexts, ranging from the de novo presentation of small cell prostatic carcinoma to a treatment-emergent transformed phenotype that arises from typical adenocarcinoma of the prostate. The development of resistance to potent androgen receptor signaling inhibition may be associated with the emergence of aggressive phenotype, advanced castration-resistant NEPC. Clinically, small cell prostate cancer and NEPC are often manifested by the presence of visceral or large soft tissue metastatic disease, a disproportionately low serum prostate-specific antigen level relative to the overall burden of disease, and a limited response to targeting of the androgen signaling axis. These tumors are often characterized by loss of androgen receptor expression, loss of retinoblastoma tumor suppressor copy number or expression, amplification of Aurora kinase A and N-Myc, and activation of the PI3K pathway. However, a consensus phenotype-genotype definition of NEPC has yet to emerge, and molecularly based biomarkers are needed to expand on traditional morphologic and immunohistochemical markers of NEPC to fully define the spectrum of this aggressive, androgen receptor-independent disease. Emerging studies implicate a shared clonal origin with prostatic adenocarcinoma in many cases, with the adaptive emergence of unique cellular programming and gene expression profiles. Ongoing clinical studies are focused on developing novel targeted therapeutic approaches for this high-risk, lethal subset of disease, to improve on the limited durations of response often observed with traditional platinum-based chemotherapy.

Correspondence: Rahul Aggarwal, MD, Department of Medicine, Division of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, Box 1711, San Francisco, CA 94143. E-mail: rahul.aggarwal@ucsf.edu
  • 1.

    Aparicio AM, Harzstark AL, Corn PG et al.. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013;19:36213630.

    • Search Google Scholar
    • Export Citation
  • 2.

    Papandreou CN, Daliani DD, Thall PF et al.. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002;20:30723080.

    • Search Google Scholar
    • Export Citation
  • 3.

    Mucci NR, Akdas G, Manely S, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol 2000;31:406414.

    • Search Google Scholar
    • Export Citation
  • 4.

    Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27:683687.

    • Search Google Scholar
    • Export Citation
  • 5.

    Berruti A, Bollito E, Cracco CM et al.. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. Prostate 2010;70:718726.

    • Search Google Scholar
    • Export Citation
  • 6.

    Hirano D, Okada Y, Minei S et al.. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45:586592.

    • Search Google Scholar
    • Export Citation
  • 7.

    Flechon A, Pouessel D, Ferlay C et al.. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011;22:24762481.

    • Search Google Scholar
    • Export Citation
  • 8.

    Evans AJ, Humphrey PA, Belani J et al.. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006;30:684693.

    • Search Google Scholar
    • Export Citation
  • 9.

    Adlakha H, Bostwick DG. Paneth cell-like change in prostate adenocarcinoma represents neuroendocrine differentiation: report of 30 cases. Hum Pathol 1994;25:135139.

    • Search Google Scholar
    • Export Citation
  • 10.

    Almagro UA. Argyrophilic prostatic carcinoma: case report with literature review on prostatic carcinoid and “carcinoid-like” prostatic carcinoma. Cancer 1985;55:608614.

    • Search Google Scholar
    • Export Citation
  • 11.

    Beltran H, Mosquera JM, Rubin MA. Neuroendocrine prostate cancer. In: Tewari A, ed. Prostate Cancer: A Comprehensive Perspective. London, England: Springer-Verlag; 2013.

    • Search Google Scholar
    • Export Citation
  • 12.

    Lotan TL, Gupta NS, Wang W et al.. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011;24:820828.

  • 13.

    Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:6571.

    • Search Google Scholar
    • Export Citation
  • 14.

    Yao JL, Madeb R, Bourne P et al.. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006;30:705712.

  • 15.

    Oesterling JE, Hauzeur CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 1992;147:804807.

    • Search Google Scholar
    • Export Citation
  • 16.

    Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology 2005;47:116.

    • Search Google Scholar
    • Export Citation
  • 17.

    Furtado P, Lima MV, Nogueira C et al.. Review of small cell carcinomas of the prostate. Prostate Cancer 2011;2011:543272.

  • 18.

    Berruti A, Mosca A, Tucci M et al.. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005;12:109117.

    • Search Google Scholar
    • Export Citation
  • 19.

    Isshiki S, Akakura K, Komiya A et al.. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167:512515.

    • Search Google Scholar
    • Export Citation
  • 20.

    Marcus DM, Goodman M, Jani AB et al.. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis 2012;15:283288.

    • Search Google Scholar
    • Export Citation
  • 21.

    Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007;14:531547.

    • Search Google Scholar
    • Export Citation
  • 22.

    Ather MH, Abbas F, Faruqui N et al.. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol 2008;8:21.

    • Search Google Scholar
    • Export Citation
  • 23.

    Lapuk AV, Wu C, Wyatt AW et al.. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012;227:286297.

    • Search Google Scholar
    • Export Citation
  • 24.

    Beltran H, Rickman DS, Park K et al.. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1:487495.

    • Search Google Scholar
    • Export Citation
  • 25.

    Wu C, Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 2007;282:35713583.

    • Search Google Scholar
    • Export Citation
  • 26.

    Ciarlo M, Benelli R, Barbieri O et al.. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/beta-catenin signaling in prostate cancer cells. Int J Cancer 2012;131:582590.

    • Search Google Scholar
    • Export Citation
  • 27.

    Pagliarini R. ERG influences cell fate decisions in prostate cancer. Presenteed at the 20th Annual Prostate Cancer Foundation Scientific Retreat; October 23-26, 2013; National Harbor, Maryland.

    • Search Google Scholar
    • Export Citation
  • 28.

    Frigo DE, McDonnell DP. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther 2008;7:659669.

    • Search Google Scholar
    • Export Citation
  • 29.

    Sequist LV, Waltman BA, Dias-Santagata D et al.. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.

    • Search Google Scholar
    • Export Citation
  • 30.

    Aparicio A, Tzelepi V, Araujo JC et al.. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient’s tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 2011;71:846856.

    • Search Google Scholar
    • Export Citation
  • 31.

    Tzelepi V, Zhang J, Lu JF et al.. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 2012;18:666677.

  • 32.

    Chiaverotti T, Couto SS, Donjacour A et al.. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236246.

    • Search Google Scholar
    • Export Citation
  • 33.

    Mohler JL, Kantoff PW, Armstrong AJ et al.. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2014. Available at NCCN.org. Accessed January 24, 2014.

    • Search Google Scholar
    • Export Citation
  • 34.

    Kalemkerian GP, Akerley W, Bogner P et al.. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 2.2014. Available at NCCN.org. Accessed January 24, 2014.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 4561 1169 90
PDF Downloads 2116 1007 58
EPUB Downloads 0 0 0